GlobeNewswire Inc.··NaNasus Pharma Advances NS002 to Pivotal Stage on Positive Phase 2 Data
Nasus Pharma reports positive Phase 2 data for NS002 intranasal epinephrine, planning pivotal study Q4 2026 with strong cash position through Q2 2027.
NSRXPhase 2 clinical trialPivotal Study